PDF herunterladen
Semin Neurol 2018; 38(03): 290-302
DOI: 10.1055/s-0038-1660860
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Autoimmune Epilepsy: The Evolving Science of Neural Autoimmunity and Its Impact on Epilepsy Management

Amy M.L. Quek
1   Division of Neurology, Department of Medicine, National University Hospital, Singapore
2   Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
,
Orna O'Toole
3   Department of Neurology, Mercy University Hospital, Grenville Place, Cork, Ireland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Juli 2018 (online)

    Lizenzen und Reprints

Abstract

Autoimmune epilepsy is increasingly recognized as a distinct clinical entity, driven in large part by the recent discovery of neural autoantibodies in patients with isolated or predominant epilepsy presentations. Detection of neural autoantibodies in high-risk epilepsy patients supports an immune-mediated cause of seizures and, if applicable, directs the search for an underlying cancer when the paraneoplastic association of the associated antibody is compelling. Early diagnosis of autoimmune epilepsy is crucial, as prompt initiation of immunosuppressive treatment increases the likelihood of achieving either seizure freedom or a substantial reduction in seizure frequency. A practical clinical approach that incorporates risk scores to guide patient selection on the basis of clinical features, neural autoantibodies, and a treatment trial of immunotherapy is suggested. Elucidating an immunological basis of epilepsy provides neurologists with wider treatment options (incorporating immune-suppressive treatment), in addition to standard antiepileptic drugs, which often improves patient outcomes.

Keywords

autoimmune - epilepsy - encephalitis - seizures - antibodies
 

  • References

  • 1 Scheffer IE, Berkovic S, Capovilla G. , et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58 (04) 512-521
    Google Scholar
  • 2 Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365 (10) 919-926
    CrossrefPubMedGoogle Scholar
  • 3 Quek AM, Britton JW, McKeon A. , et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69 (05) 582-593
    CrossrefPubMedGoogle Scholar
  • 4 Barajas RF, Collins DE, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 2010; 51 (03) 473-477
    CrossrefPubMedGoogle Scholar
  • 5 Toledano M, Britton JW, McKeon A. , et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82 (18) 1578-1586
    CrossrefPubMedGoogle Scholar
  • 6 McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122 (04) 381-400
    CrossrefPubMedGoogle Scholar
  • 7 Greenlee JE, Clawson SA, Hill KE. , et al. Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. J Neuroinflammation 2014; 11: 160
    CrossrefPubMedGoogle Scholar
  • 8 Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56 (05) 715-719
    CrossrefPubMedGoogle Scholar
  • 9 Horta ES, Lennon VA, Lachance DH. , et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res 2014; 20 (14) 3862-3869
    CrossrefPubMedGoogle Scholar
  • 10 Dubey D, Alqallaf A, Hays R. , et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 2017; 74 (04) 397-402
    CrossrefPubMedGoogle Scholar
  • 11 Dubey D, Singh J, Britton JW. , et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 2017; 58 (07) 1181-1189
    CrossrefPubMedGoogle Scholar
  • 12 Majoie HJ, de Baets M, Renier W, Lang B, Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006; 71 (2-3): 135-141
    CrossrefPubMedGoogle Scholar
  • 13 Errichiello L, Striano S, Zara F, Striano P. Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity. Neurol Sci 2011; 32 (04) 547-550
    CrossrefPubMedGoogle Scholar
  • 14 Liimatainen S, Peltola M, Sabater L. , et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010; 51 (05) 760-767
    CrossrefPubMedGoogle Scholar
  • 15 McKnight K, Jiang Y, Hart Y. , et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65 (11) 1730-1736
    CrossrefPubMedGoogle Scholar
  • 16 Brenner T, Sills GJ, Hart Y. , et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013; 54 (06) 1028-1035
    CrossrefPubMedGoogle Scholar
  • 17 Ekizoglu E, Tuzun E, Woodhall M. , et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia 2014; 55 (03) 414-422
    CrossrefPubMedGoogle Scholar
  • 18 Suleiman J, Wright S, Gill D. , et al. Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia 2013; 54 (12) 2091-2100
    CrossrefPubMedGoogle Scholar
  • 19 Dalmau J, Gleichman AJ, Hughes EG. , et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 20 Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology 2011; 76 (20) 1750-1757
    CrossrefPubMedGoogle Scholar
  • 21 Granerod J, Ambrose HE, Davies NW. , et al; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10 (12) 835-844
    CrossrefPubMedGoogle Scholar
  • 22 Niehusmann P, Dalmau J, Rudlowski C. , et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009; 66 (04) 458-464
    PubMedGoogle Scholar
  • 23 Hughes EG, Peng X, Gleichman AJ. , et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30 (17) 5866-5875
    CrossrefPubMedGoogle Scholar
  • 24 Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 76 (01) 108-119
    CrossrefPubMedGoogle Scholar
  • 25 Titulaer MJ, McCracken L, Gabilondo I. , et al. Late-onset anti-NMDA receptor encephalitis. Neurology 2013; 81 (12) 1058-1063
    CrossrefPubMedGoogle Scholar
  • 26 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10 (01) 63-74
    CrossrefPubMedGoogle Scholar
  • 27 Titulaer MJ, McCracken L, Gabilondo I. , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 28 Bayreuther C, Bourg V, Dellamonica J, Borg M, Bernardin G, Thomas P. Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. Epileptic Disord 2009; 11 (03) 261-265
    PubMedGoogle Scholar
  • 29 Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79 (11) 1094-1100
    CrossrefPubMedGoogle Scholar
  • 30 Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62 (07) 1177-1182
    CrossrefPubMedGoogle Scholar
  • 31 Irani SR, Buckley C, Vincent A. , et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008; 71 (20) 1647-1648
    CrossrefPubMedGoogle Scholar
  • 32 Lai M, Huijbers MG, Lancaster E. , et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9 (08) 776-785
    CrossrefPubMedGoogle Scholar
  • 33 Irani SR, Alexander S, Waters P. , et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133 (09) 2734-2748
    CrossrefPubMedGoogle Scholar
  • 34 Lancaster E, Huijbers MG, Bar V. , et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69 (02) 303-311
    CrossrefPubMedGoogle Scholar
  • 35 Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018; 89 (05) 526-534
    CrossrefPubMedGoogle Scholar
  • 36 van Sonderen A, Thijs RD, Coenders EC. , et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016; 87 (14) 1449-1456
    CrossrefPubMedGoogle Scholar
  • 37 van Sonderen A, Ariño H, Petit-Pedrol M. , et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016; 87 (05) 521-528
    CrossrefPubMedGoogle Scholar
  • 38 Fukata Y, Lovero KL, Iwanaga T. , et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010; 107 (08) 3799-3804
    CrossrefPubMedGoogle Scholar
  • 39 Kalachikov S, Evgrafov O, Ross B. , et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002; 30 (03) 335-341
    CrossrefPubMedGoogle Scholar
  • 40 Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002; 52 (03) 364-367
    CrossrefPubMedGoogle Scholar
  • 41 Poliak S, Salomon D, Elhanany H. , et al. Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 2003; 162 (06) 1149-1160
    CrossrefPubMedGoogle Scholar
  • 42 Poliak S, Gollan L, Martinez R. , et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 1999; 24 (04) 1037-1047
    CrossrefPubMedGoogle Scholar
  • 43 Strauss KA, Puffenberger EG, Huentelman MJ. , et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006; 354 (13) 1370-1377
    CrossrefPubMedGoogle Scholar
  • 44 Rodenas-Cuadrado P, Ho J, Vernes SC. Shining a light on CNTNAP2: complex functions to complex disorders. Eur J Hum Genet 2014; 22 (02) 171-178
    CrossrefPubMedGoogle Scholar
  • 45 Pinatel D, Hivert B, Boucraut J. , et al. Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. Front Cell Neurosci 2015; 9: 265
    PubMedGoogle Scholar
  • 46 van Sonderen A, Schreurs MW, de Bruijn MA. , et al. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology 2016; 86 (18) 1692-1699
    CrossrefPubMedGoogle Scholar
  • 47 Irani SR, Michell AW, Lang B. , et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69 (05) 892-900
    CrossrefPubMedGoogle Scholar
  • 48 Irani SR, Stagg CJ, Schott JM. , et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136 (Pt 10): 3151-3162
    CrossrefPubMedGoogle Scholar
  • 49 Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Seizure 2017; 50: 14-17
    CrossrefPubMedGoogle Scholar
  • 50 Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?. Neurology 2011; 76 (15) 1355-1357
    CrossrefPubMedGoogle Scholar
  • 51 Rocamora R, Becerra JL, Fossas P. , et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis?. Seizure 2014; 23 (08) 670-673
    CrossrefPubMedGoogle Scholar
  • 52 Kotsenas AL, Watson RE, Pittock SJ. , et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014; 35 (01) 84-89
    CrossrefPubMedGoogle Scholar
  • 53 Sunwoo JS, Lee ST, Byun JI. , et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 2015; 281: 17-22
    CrossrefPubMedGoogle Scholar
  • 54 Joubert B, Saint-Martin M, Noraz N. , et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 2016; 73 (09) 1115-1124
    CrossrefPubMedGoogle Scholar
  • 55 Baysal-Kirac L, Tuzun E, Erdag E. , et al. Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings. J Neurol 2016; 263 (03) 455-466
    CrossrefPubMedGoogle Scholar
  • 56 Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012; 78 (08) 578-584
    CrossrefPubMedGoogle Scholar
  • 57 Lancaster E, Lai M, Peng X. , et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9 (01) 67-76
    CrossrefPubMedGoogle Scholar
  • 58 Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76 (09) 795-800
    CrossrefPubMedGoogle Scholar
  • 59 Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013; 81 (10) 882-887
    CrossrefPubMedGoogle Scholar
  • 60 Höftberger R, Titulaer MJ, Sabater L. , et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013; 81 (17) 1500-1506
    CrossrefPubMedGoogle Scholar
  • 61 Petit-Pedrol M, Armangue T, Peng X. , et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13 (03) 276-286
    CrossrefPubMedGoogle Scholar
  • 62 Spatola M, Petit-Pedrol M, Simabukuro MM. , et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology 2017; 88 (11) 1012-1020
    CrossrefPubMedGoogle Scholar
  • 63 Ohkawa T, Satake S, Yokoi N. , et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci 2014; 34 (24) 8151-8163
    CrossrefPubMedGoogle Scholar
  • 64 Benarroch EE. GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology 2007; 68 (08) 612-614
    CrossrefPubMedGoogle Scholar
  • 65 Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5 (07) 553-564
    CrossrefPubMedGoogle Scholar
  • 66 Zhou C, Huang Z, Ding L. , et al. Altered cortical GABAA receptor composition, physiology, and endocytosis in a mouse model of a human genetic absence epilepsy syndrome. J Biol Chem 2013; 288 (29) 21458-21472
    CrossrefPubMedGoogle Scholar
  • 67 Tanaka M, Olsen RW, Medina MT. , et al. Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am J Hum Genet 2008; 82 (06) 1249-1261
    CrossrefPubMedGoogle Scholar
  • 68 Pettingill P, Kramer HB, Coebergh JA. , et al. Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization. Neurology 2015; 84 (12) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 69 Lai M, Hughes EG, Peng X. , et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65 (04) 424-434
    CrossrefPubMedGoogle Scholar
  • 70 Joubert B, Kerschen P, Zekeridou A. , et al. Clinical spectrum of encephalitis associated with antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: case series and review of the literature. JAMA Neurol 2015; 72 (10) 1163-1169
    CrossrefPubMedGoogle Scholar
  • 71 Höftberger R, van Sonderen A, Leypoldt F. , et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015; 84 (24) 2403-2412
    CrossrefPubMedGoogle Scholar
  • 72 Dogan Onugoren M, Deuretzbacher D, Haensch CA. , et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 2015; 86 (09) 965-972
    CrossrefPubMedGoogle Scholar
  • 73 Graus F, Boronat A, Xifró X. , et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010; 74 (10) 857-859
    CrossrefPubMedGoogle Scholar
  • 74 Bataller L, Galiano R, García-Escrig M. , et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010; 74 (03) 265-267
    CrossrefPubMedGoogle Scholar
  • 75 Saiz A, Blanco Y, Sabater L. , et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131 (Pt 10): 2553-2563
    CrossrefPubMedGoogle Scholar
  • 76 Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67 (04) 470-478
    CrossrefPubMedGoogle Scholar
  • 77 Lilleker JB, Biswas V, Mohanraj R. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 2014; 23 (08) 598-602
    CrossrefPubMedGoogle Scholar
  • 78 Pittock SJ, Yoshikawa H, Ahlskog JE. , et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81 (09) 1207-1214
    CrossrefPubMedGoogle Scholar
  • 79 Ariño H, Höftberger R, Gresa-Arribas N. , et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 2015; 72 (08) 874-881
    CrossrefPubMedGoogle Scholar
  • 80 Malter MP, Frisch C, Zeitler H. , et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure 2015; 30: 57-63
    CrossrefPubMedGoogle Scholar
  • 81 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50 (03) 652-657
    CrossrefPubMedGoogle Scholar
  • 82 Graus F, Keime-Guibert F, Reñe R. , et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (Pt 6): 1138-1148
    CrossrefPubMedGoogle Scholar
  • 83 Rudzinski LA, Pittock SJ, McKeon A, Lennon VA, Britton JW. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res 2011; 95 (03) 255-262
    CrossrefPubMedGoogle Scholar
  • 84 Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994; 44 (01) 140-147
    CrossrefPubMedGoogle Scholar
  • 85 Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49 (02) 146-154
    CrossrefPubMedGoogle Scholar
  • 86 Cross SA, Salomao DR, Parisi JE. , et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54 (01) 38-50
    CrossrefPubMedGoogle Scholar
  • 87 Dalmau J, Graus F, Villarejo A. , et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127 (Pt 8): 1831-1844
    CrossrefPubMedGoogle Scholar
  • 88 Lichte B, Veh RW, Meyer HE, Kilimann MW. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J 1992; 11 (07) 2521-2530
    PubMedGoogle Scholar
  • 89 Pittock SJ, Lucchinetti CF, Parisi JE. , et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58 (01) 96-107
    CrossrefPubMedGoogle Scholar
  • 90 Toledano M, Pittock SJ. Autoimmune epilepsy. Semin Neurol 2015; 35 (03) 245-258
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 91 Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e353
    CrossrefPubMedGoogle Scholar
  • 92 Herlopian A, Rosenthal ES, Chu CJ, Cole AJ, Struck AF. Extreme delta brush evolving into status epilepticus in a patient with anti-NMDA encephalitis. Epilepsy Behav Case Rep 2016; 7: 69-71
    PubMedGoogle Scholar
  • 93 Baysal-Kirac L, Tuzun E, Altindag E. , et al. Are there any specific EEG findings in autoimmune epilepsies?. Clin EEG Neurosci 2016; 47 (03) 224-234
    CrossrefPubMedGoogle Scholar
  • 94 Dubey D, Farzal Z, Hays R, Brown LS, Vernino S. Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis. Ther Adv Neurol Disorder 2016; 9 (05) 369-377
    PubMedGoogle Scholar
  • 95 McKeon A, Lennon VA. NMDAR encephalitis: which specimens, and the value of values. Lancet Neurol 2014; 13 (02) 133-135
    CrossrefPubMedGoogle Scholar
  • 96 Bien CG, Holtkamp M. “Autoimmune epilepsy”: encephalitis with autoantibodies for epileptologists. Epilepsy Curr 2017; 17 (03) 134-141
    CrossrefPubMedGoogle Scholar
  • 97 McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011; 76 (12) 1108-1110
    CrossrefPubMedGoogle Scholar
  • 98 Bien CG. Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management. Epilepsia 2013; 54 (Suppl. 02) 48-55
    CrossrefPubMedGoogle Scholar
  • 99 McKeon A, Apiwattanakul M, Lachance DH. , et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010; 67 (03) 322-329
    CrossrefPubMedGoogle Scholar